FASN and prostate carcinoma: Thus, metformin effectively blocks lipogenesis by inhibiting activation or expression of lipid biosynthesis enzymes such as acetyl Co-A carboxylase (ACC) and fatty acid synthase (FASN), key regulators of the metabolic reprogramming identified in prostate cancer [70].